Table 1.

Characteristics and outcome of treatment with LowR-BD in patients with wAIHA.

Patient	Sex	Age (years)	Diagnosis	Disease duration	Previous treatment	HGB (g/L) before treatment	RBC (∗1012/L) before treatment	Ret (%) before treatment	Transfusion during previous treatment (U)	Days to elevation of HGB > 20 g/L	LowR-BD treatment cycle	Transfusion during LowR-BD treatment (U)	Response after LowR-BD	Time to PR (days)	Time to CR (days)	Follow-up
1	F	65	Evans syndrome, SLE, wAIHA	18 mo	GCs	64	2.23	5.03	0	10	4	2	PR	10	24	CCR
2	F	61	wAIHA	2 mo	FD, PE	63	1.76	10.83	0	9	4	4	CR	9	11	CCR
3	F	48	RA, MBL, wAIHA	1 mo	GCs	54	1.86	8.61	0	8	4	4	CR	8	28	CCR
4	M	39	wAIHA	2 d	FD, PE	58	1.82	13.32	0	7	4	4	CR	7	15	CCR
5	M	74	wAIHA	15 d	GCs	50	1.15	23.22	4	23	4	0	NR	95	233	Reached CR after using CYC for 6. 5 mo
6	F	48	wAIHA, WM	6 yr	COP, Spl, GCs, Rtx, PE, CYC	47	1.08	14.69	18	14	4	4	CR	14	21	Relapse 10 mo later, PR was achieved after treatment with 2 cycles of LowR-BD.
7	M	70	wAIHA, SS	9 mo	GCs, HCQ, TGs, PE, CsA, Rtx, MMF	47	1.05	7.61	12	18	3	12 + 4	PR	26	–	PR

CCR = continuous complete response, COP = cyclophosphamide + vincristine + prednisone, CR = complete response, CsA = ciclosporin, CYC = cyclophosphamide, F = female, FD = first diagnosis, GCs = glucocorticoids, HCQ = hydroxychloroquine, HGB = haemoglobin, LowR-BD = rituximab + bortezomib + dexamethasone, M = male, MBL = Monoclonal B-cell lymphocytosis, MMF = mycophenolate mofetil, PE = plasma exchange, PR = partial response, RA = rheumatoid arthritis, RBC = red blood cell, Ret = reticulocyte, Rtx = rituximab, SLE = systemic lupus erythematous, Spl = splenectomy, SS = Sjogrensyndrome, TGs = Tripterygium glycosides, wAIHA = warm autoimmune hemolytic anemia, WM = waldenstrom macroglobulinaemia.